Share loss in insulin pen needles, market volume softness, and a U.S. revenue shortfall caused a major earnings miss in ...

Embecta's most recent quarterly report didn't give investors much to be exicited about.

Embecta faces accelerating revenue declines, with Q2 2026 sales down 14% and U.S. revenues plunging 29%. Click here to read ...

There's been a major selloff in Embecta Corp. (NASDAQ:EMBC) shares in the week since it released its second-quarter report, with the stock down 61% to US$3.60. It was a pretty neg ...

Embecta shares fell sharply premarket after the maker of medical supplies lowered growth projections for the fiscal year and reduced its quarterly dividend on the heels of weak second-quarter earnings ...

Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported second quarter ...

The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each ...

Embecta’s latest earnings call balanced long-term strategic steps with stark near-term pain. Management touted the Owen Mumford acquisition, GLP‑1 partnerships, and solid liquidity, yet the discussion ...

Q2 fiscal 2026 Management View "This was a difficult quarter for embecta." (President, CEO & Chairman Devdatt Kurdikar) "Our results were below expectations with consolidated revenues down 14.4% ...

Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the 2026 BofA Securities Global Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 3:00 p.m. PT / ...

The January ribbon cutting at embecta‘s new global headquarters in Parsippany was the latest step for one of the world’s largest pure-play diabetes management companies. “It was a really important ...